Acumen Pharmaceuticals, Inc. (ABOS)
NASDAQ:ABOS
Want to see ABOS full AI Analyst Report?
ABOS Stock Chart & Stats
$2.82
-$0.08(-4.37%)
At close: 4:00 PM EST
$2.82
-$0.08(-4.37%)
Day’s Range― - ―
52-Week Range$1.10 - $3.60
Previous CloseN/A
Volume101.31K
Average Volume (3M)359.03K
Market Cap
$163.23M
Enterprise Value$115.66M
Total Cash (Recent Filing)$128.40M
Total Debt (Recent Filing)$31.16M
Price to Earnings (P/E)―
Beta2.29
Next Earnings
Aug 17, 2026EPS Estimate
-0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.87
Shares Outstanding72,227,580
10 Day Avg. Volume430,370
30 Day Avg. Volume359,028
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)1.81
Price to Sales (P/S)0.00
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.51K
Enterprise Value/Ebitda-1.06
Forecast
1Y Price Target
$8.00Price Target Upside183.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.42
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enhanced Brain Delivery (EBD) DifferentiationPreclinical 14–40× higher brain exposure for EBD candidates indicates a structural pharmacologic advantage versus native antibodies. Improved brain penetration and distribution can materially increase target engagement, broaden treatable populations, and create durable differentiation versus competitors if safety translates in humans.
Clinical Execution And Enrollment EfficiencyRapid, well-powered enrollment and use of plasma p-tau217 to cut negative PET rates reduced timelines and selection costs. Consistent trial execution and biomarker-driven screening are durable operational capabilities that lower future study risk, improve data quality, and speed development across the pipeline.
Cash Buffer And Reduced LeverageA recent private placement meaningfully increased liquidity and the balance sheet shows lower leverage, providing a clearer near‑term funding base. While runway is finite, having >$100M and modest debt improves optionality for IND enabling work and candidate advancement without immediate debt pressure.
Bears Say
High Cash Burn And Runway RiskSustained negative operating and free cash flow (~- $106M TTM) means the company must secure additional financing within months to sustain development. Recurrent capital raises dilute shareholders and create execution risk if market conditions or trial timelines shift, making financing a persistent structural vulnerability.
Pre‑commercial With No RevenueAs a clinical-stage biotech with no product revenue, Acumen relies entirely on capital markets and partnerships to fund R&D. Large, growing net losses that translate into cash outflows reduce financial flexibility and increase dilution risk over the medium term until a commercial product or sustained partner income emerges.
Binary Clinical And Timing UncertaintyThe company’s strategic value hinges on a binary Phase II readout and preclinical EBD milestones. Negative or ambiguous Phase II results or delays would materially impair commercialization prospects and partner interest. The EBD program’s preclinical status adds multi-year execution and regulatory risk before commercialization is plausible.
Acumen Pharmaceuticals News
ABOS FAQ
What was Acumen Pharmaceuticals, Inc.’s price range in the past 12 months?
Acumen Pharmaceuticals, Inc. lowest stock price was $1.10 and its highest was $3.60 in the past 12 months.
What is Acumen Pharmaceuticals, Inc.’s market cap?
Acumen Pharmaceuticals, Inc.’s market cap is $163.23M.
When is Acumen Pharmaceuticals, Inc.’s upcoming earnings report date?
Acumen Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Acumen Pharmaceuticals, Inc.’s earnings last quarter?
Acumen Pharmaceuticals, Inc. released its earnings results on May 12, 2026. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.403 by $0.073.
Is Acumen Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Acumen Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Acumen Pharmaceuticals, Inc. pay dividends?
Acumen Pharmaceuticals, Inc. does not currently pay dividends.
What is Acumen Pharmaceuticals, Inc.’s EPS estimate?
Acumen Pharmaceuticals, Inc.’s EPS estimate is -0.36.
How many shares outstanding does Acumen Pharmaceuticals, Inc. have?
Acumen Pharmaceuticals, Inc. has 72,227,580 shares outstanding.
What happened to Acumen Pharmaceuticals, Inc.’s price movement after its last earnings report?
Acumen Pharmaceuticals, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.403. Following the earnings report the stock price went down -3.502%.
Which hedge fund is a major shareholder of Acumen Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ABOS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acumen Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (183.69% Upside)
$8.00 (183.69% Upside)
Blogger Sentiment
Bullish
ABOS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 6.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $89.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.24%
12-Months-Change
Fundamentals
Return on Equity
-123.07%
Trailing 12-Months
Asset Growth
-34.65%
Trailing 12-Months
Company Description
Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
ABOS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a generally positive tone driven by on-track clinical execution (ALTITUDE-AD), imminent milestones (ALTITUDE top-line readout late 2026; licensing decision for two EBD candidates in Q2 2026), encouraging preclinical EBD data (≈14–40x brain exposure), and controlled operating expenses. Key risks tempering the outlook include a cash runway only into early 2027 (necessitating future financing if programs extend), pending binary Phase II results that will determine the program's trajectory, competition and skepticism around the amyloid class, and the EBD program still being preclinical with an IND targeted for mid-2027.View all ABOS earnings summariesABOS Stock 12 Month Forecast
Average Price Target
$8.00
▲(183.69% Upside)
Technical Analysis
Ownership Overview
32.76% Insiders
6.55% Mutual Funds
45.98% Other Institutional Investors
12.29% Public Companies and
Individual Investors